Feb 13, 2018
CAMBRIDGE, Mass. – February 13, 2018 ReForm Biologics, a pharmaceutical technology company developing innovative platforms to improve biologic formulations, expanded its patent portfolio with the issuance of U.S. Patent No. 9,867,881 (the ‘881 patent). This patent,...
Feb 7, 2018
AbSci says its genetically engineered E. coli expression platform has produced yields exceeding 20 g/L for difficult to express products and threatens the dominance of mammalian systems. Read the full article here: biopharma-reporter.com
Feb 5, 2018
VANCOUVER, Wash., Feb. 5, 2018 /PRNewswire AbSci, announced the addition of Coherus Biosciences’ (NASDAQ: CHRS) Chief Scientific Officer, Alan Herman, PhD to its Scientific Advisory Board. Dr. Herman brings over 30 years of industry experience with expertise in...
